2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Personalized Therapy In Cancer
Personalized therapy in cancer marks a groundbreaking shift from one-size-fits-all treatments to tailored approaches based on an individual's genetic makeup, tumor characteristics, and other factors. This approach leverages cutting-edge technologies like next-generation sequencing to analyze a patient's tumor at the molecular level, identifying specific mutations and biomarkers that drive cancer growth. Armed with this information, oncologists can prescribe targeted therapies that precisely address the unique vulnerabilities of each tumor, maximizing effectiveness while minimizing side effects. Additionally, personalized therapy extends beyond genomic profiling, encompassing immunotherapies that harness the body's immune system to fight cancer. By customizing treatment strategies to the intricacies of each patient's disease, personalized therapy represents a paradigm shift in cancer care, offering new hope for improved outcomes and quality of life.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China